Hospital
Santa Barbara Cottage Hospital
Santa Barbara Cottage Hospital was paid $13.50M by Medicaid between Jan 2018 and Nov 2024, across 140 billing codes. Its largest line is 0450, Emergency room services — 73% of everything it billed.
33Billing provider infoSANTA BARBARA COTTAGE HOSPITAL
SANTA BARBARA, CA 93105
SANTA BARBARA, CA 93105
33aNPI1477554152assigned 08/03/2005
33bProvider typeRehabilitation Hospital Unit
28Total paid$13.50M
24GClaims330,906
24DCodes billed140
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in California
Rank by total paid#7 of 22
Median peer was paid$308K
This provider vs. median44×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,305 | $2.18M | |
| 2019 | 52,814 | $2.34M | |
| 2020 | 44,476 | $1.80M | |
| 2021 | 66,056 | $2.65M | |
| 2022 | 62,850 | $2.23M | |
| 2023 | 36,290 | $1.49M | |
| 2024incomplete | 13,115 | $808K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 73% | 64,660 | 53,884 | $9.79M |
| 0761 | 5.8% | 21,132 | 20,235 | $780K | |
| 0250 | 2.4% | 70,219 | 25,973 | $321K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 2,847 | 2,699 | $301K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 4,125 | 1,913 | $239K |
| 0370 | 1.7% | 515 | 493 | $228K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.6% | 2,486 | 2,343 | $215K |
| 0360 | 1.4% | 1,609 | 1,041 | $192K | |
| 0002A | 1.3% | 4,412 | 4,412 | $176K | |
| 0001A | 1.3% | 4,405 | 4,405 | $171K | |
| Z7502 | 1.0% | 3,636 | 3,603 | $136K | |
| 0510 | <1% | 3,684 | 3,610 | $97K |
128 more codes
| 0301 | <1% | 58,208 | $86K | |
| A4649 | Surgical supply; miscellaneous | <1% | 1,880 | $73K |
| 0762 | <1% | 382 | $68K | |
| 0483 | <1% | 336 | $51K | |
| 96379 | <1% | 1,761 | $40K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,420 | $39K |
| 0710 | <1% | 1,580 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 759 | $36K |
| 0480 | <1% | 419 | $33K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,451 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 299 | $29K |
| 99285 | Emergency room visit (most serious) | <1% | 872 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,528 | $29K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 148 | $23K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 575 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 591 | $16K |
| 0403 | <1% | 154 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,683 | $14K |
| 93325 | <1% | 149 | $13K | |
| 0305 | <1% | 17,424 | $11K | |
| 93320 | <1% | 143 | $10K | |
| 0272 | <1% | 508 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 299 | $7K |
| 99070 | <1% | 12,552 | $7K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 349 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 355 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 129 | $6K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 105 | $6K |
| Z7500 | <1% | 148 | $5K | |
| 0740 | <1% | 73 | $5K | |
| J3490 | Unclassified drugs | <1% | 273 | $5K |
| 82077 | <1% | 168 | $5K | |
| 0921 | <1% | 209 | $5K | |
| 0420 | <1% | 102 | $4K | |
| 59025 | Fetal non-stress test | <1% | 188 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 108 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 148 | $4K |
| 0730 | <1% | 1,054 | $3K | |
| 0611 | <1% | 12 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 465 | $3K |
| Q3014 | Telehealth originating site facility fee | <1% | 135 | $3K |
| 95812 | <1% | 46 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 386 | $3K |
| 96150 | <1% | 398 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 656 | $3K |
| 0750 | <1% | 21 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 67 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 292 | $2K |
| 0320 | <1% | 3,111 | $2K | |
| Z7514 | <1% | 32 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 519 | $2K |
| 0260 | <1% | 1,714 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 227 | $2K |
| 84484 | <1% | 862 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 174 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 173 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 18 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 848 | $1K |
| 83690 | <1% | 655 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 43 | $1K |
| 82805 | <1% | 227 | $996.72 | |
| 81003 | <1% | 798 | $980.02 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 905 | $962.40 |
| 0003A | <1% | 24 | $960.00 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 230 | $835.31 |
| 0307 | <1% | 691 | $802.84 | |
| 0011A | <1% | 41 | $694.54 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 542 | $666.20 |
| 85027 | <1% | 306 | $606.60 | |
| 0258 | <1% | 444 | $563.55 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $534.66 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 607 | $527.83 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $482.28 |
| Z7610 | <1% | 381 | $463.61 | |
| 83735 | <1% | 132 | $433.06 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 558 | $418.42 |
| 0760 | <1% | 12 | $409.20 | |
| 82375 | <1% | 227 | $399.85 | |
| 83605 | <1% | 214 | $380.85 | |
| 81001 | <1% | 605 | $370.56 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 241 | $364.17 |
| 82947 | <1% | 543 | $336.98 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 59 | $332.62 |
| 0270 | <1% | 37 | $300.07 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 62 | $272.25 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 194 | $270.07 |
| 99152 | <1% | 54 | $251.36 | |
| 85007 | <1% | 154 | $243.64 | |
| 84703 | <1% | 79 | $221.82 | |
| 83615 | <1% | 51 | $218.91 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 826 | $217.05 |
| 85610 | <1% | 322 | $203.19 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $203.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 212 | $202.89 |
| 83880 | <1% | 42 | $183.08 | |
| 84100 | <1% | 52 | $174.73 | |
| C1769 | Guide wire | <1% | 14 | $168.51 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 134 | $151.98 |
| 86140 | <1% | 182 | $150.27 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 56 | $133.66 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 30 | $132.71 |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 44 | $126.13 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $125.00 |
| 80047 | <1% | 93 | $107.52 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 195 | $99.35 |
| 87040 | <1% | 68 | $67.11 | |
| 80076 | <1% | 26 | $61.69 | |
| 87077 | <1% | 73 | $58.66 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 66 | $47.89 |
| 36600 | <1% | 12 | $44.05 | |
| 85379 | <1% | 13 | $32.50 | |
| 80069 | <1% | 12 | $30.40 | |
| 86901 | <1% | 36 | $25.07 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 44 | $24.99 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 12 | $24.24 |
| 86850 | <1% | 12 | $23.00 | |
| 0306 | <1% | 371 | $21.60 | |
| 86900 | <1% | 24 | $11.80 | |
| 87186 | <1% | 12 | $6.06 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13 | $4.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 27 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 90 | $0.00 |
| 0302 | 0% | 28 | $0.00 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 34 | $0.00 |
| 0352 | 0% | 29 | $0.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 32 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 54 | $0.00 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORGAN, MATTHEW (SENIOR VICE PRESIDENT AND CHIEF FIN)
| Provider | Location | Paid |
|---|---|---|
| Community Hospital of the Monterey Peninsula | Monterey, CA | $88.46M |
| Community Hospital of the Monterey Peninsula | Monterey, CA | $9.95M |
| Goleta Valley Cottage Hospital | Santa Barbara, CA | $4.72M |
| Santa Ynez Valley Cottage Hospital, INC | Solvang, CA | $1.67M |
| Covenant Family Wellness, LLC | Reynoldsburg, OH | $132K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.